期刊文献+

老年帕金森病轻度认知损害患者踝臂指数、超敏C反应蛋白的临床研究 被引量:2

Clinical Study of Ankle-Brachial Index and High-Sensitivity C-Reactive Protein in Elderly Patients with Parkinson's Disease and Mild Cognitive Impairment
下载PDF
导出
摘要 目的探讨踝臂指数(ABI)、血清超敏C反应蛋白(hs-CRP)与老年帕金森病合并轻度认知损害(PD-MCI)的关系。方法 89例老年帕金森病患者,其中合并轻度认知损害43例(PD-MCI组),无合并轻度认知损害46例(单纯PD组),健康对照组46例,采用全自动动脉硬化BP203RPE-II检测仪检测各组对象ABI,采用酶比色法测定血清hs-CRP水平。结果 PD-MCI组、单纯PD组患者ABI均低于对照组(P<0.05),PD-MCI组与单纯PD组ABI比较,差异无统计学意义(P>0.05)。PD-MCI组hs-CRP水平高于对照组、单纯PD组(P<0.05),单纯PD组hs-CRP水平与对照组比较,差异无统计学意义(P>0.05)。结论老年帕金森病患者ABI下降,PD-MCI患者血hs-CRP水平升高。hs-CRP水平升高可能是反映PD-MCI的指标。 Objective To study the relationship between ankle-brachial index( ABI),serum high-sensitivity C-reactive protein( hs-CRP) and elderly Parkinson's disease with mild cognitive impairment( PD-MCI). Methods Eighty-nine cases of elder Parkinson' s disease were divided into 2 groups: 43 cases with mild cognitive impairment( PD-MCI group) and 46 cases without mild cognitive impairment( pure PD group),respectively. Forty-six cases of the healthy elders were selected as control group. ABI of all observers was detected by full-automatic arteriosclerosis( BP203RPE-Ⅱ),and serum hs-CRP level was examined by enzyme colorimetry. Results The ABI in the PD-MCI group,pure PD group was lower than that in the control group( P〈0. 05). The ABI showed no significant difference between PD-MCI group and pure PD group( P〉0. 05). The hs-CRP level in the PD-MCI group was higher than that in the control group or pure PD group( P〈0. 05),while the hs-CRP level showed no significant difference between pure PD group and control group( P〉0. 05). Conclusion Lower ABI can be observed in elderly patients with Parkinson's disease. The hs-CRP level increases in PD-MCI patients,which indicates the increase of hs-CRP level may be an index of PD-MCI.
出处 《广西医学》 CAS 2014年第9期1237-1239,共3页 Guangxi Medical Journal
基金 广西南宁市科学研究与技术开发计划项目(200802105C)
关键词 帕金森病 踝臂指数 超敏C反应蛋白 认知损害 Parkinson's disease Ankle-brachial index High-sensitivity C-reactive protein Cognitive impairment
  • 相关文献

参考文献16

  • 1Emre M. Dementia associated with Parkinson's disease[ J]. Lancet Neurol,2003,2 (4) :229 - 237.
  • 2Muslimovic D, Post B, Speelman JD, et al. Cognitive profile of patients with newly diagnosed Parkinson disease [ J]. Neurology,2005,65(8) :1 239- 1 245.
  • 3Pan PL, Song W, Shang HF. Voxel-wise meta-analysis of gray matter abnormalities in idiopathic Parkinson's disease [J]. Eur J Neurol,2012,19(2) :199 -206.
  • 4Folstein MF,Folstein SE,McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician[J]. J Psychiatr Res,1975,12(3) :189 - 198.
  • 5HAMILTON M. The assessment of anxiety states by rating [J]. Br J Med Paychol,1959,32(1) :50 -55.
  • 6汪向东,王希林,马弘,等.心理卫生评定量表手册[M].北京:中国心理卫生杂志社,1999.
  • 7张振馨.帕金森病的诊断[J].中华神经科杂志,2006,39(6):408-409. 被引量:616
  • 8Hauk L. ACCF/AHA update peripheral artery disease man- agement guideline [ J ]. Am Fain Physician,2012,85 (10) : 1 000- 1 001.
  • 9Shoffner JM, Watts RL, Juncos JL, et al. Mitochondrial oxi- dative phosphorylation defects in Parkinson's disease [ J ]. Ann Nettrol, 1991,30 ( 3 ) : 332 - 339.
  • 10Parker WD Jr, Boyson SJ, Parks JK. Abnormalities of the e- lectron transport chain in idiopathic Parkinson's disease [ J ]. Ann Neurol, 1989,26 (6) :719 - 723.

二级参考文献60

  • 1Calne DB,Snow BJ,Lee C.Criteria for diagnosing Parkinson's disease.Ann Neurol,1992,32 Suppl:125-127.
  • 2Gelb GJ,Oliver E,Gilman S.Diagnostic criteria for Parkinson's disease.Arch Neurol,1999,56:33-39.
  • 3Gibb WRG.The neuropathology of Parkinson's disease.In:Jankovic J,Tolosa E,eds.Parkinson's disease and movement disorders.Baltimore:Urban and Schwarzenberg,1988.205-223.
  • 4Koller WC.How accurately can Parkinson's disease be diagnosed?Neurology,1992,42Suppl 1:6-16.
  • 5Paulson HL,Stern M.Clinical Manifestations of Parkinson's disease.In:Watts RL,Koller WC,eds.Movement disorders.New York:McGraw-Hill,2004.233-245.
  • 6Hughes AJ,Daniel SE,Kilford L,et al.Accuracy of clinical diagnosis of idiopathic Parkinson's disease:a clinico-pathological study of 100 cases.J Neurol Neurosurg Psychiatry,1992,55:181-184.
  • 7The Guideline Review Panel of NICE (the national institute for clinical excellence).Diagnosis and management in primary and secondary care.In Parkinson's disease--full guideline,second consultation,2006.34-38.
  • 8Ramirez BG, Blazquez C, G6mez del Pulgar T, et al. Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. J Neurosci, 2005, 25(8): 1904-1913.
  • 9Holm TH, Draeby D, Owens T. Microglia is required for astroglial toll -like receptor 4 response and foroptirnal TLR2 and TLR3 response. Glia, 2012, 60( 4): 630-638.
  • 10Prinz M, Garbe F, Schmidt H, et al. Innate immunity mediated by TLR9 modulates pathogenicity in an animal model of multiple sclerosis. J Clin Invest, 2006, 116(2): 456-464.

共引文献2629

同被引文献28

  • 1Dauer W,Przedborski S.Parkinson's disease:mechanisms and models[J].Neuron,2003,39(6):889-909.
  • 2Brundin P.GDNF treatment in Parkinson's disease:time for controlled clinical trials[J].Brain,2002,125(Pt 10):2149-2151.
  • 3Brodbeck S,Besenbeck B,Englert C.The transcription factor Six2activates expression of the Gdnf gene as well as its own promoter[J].Mech Dev,2004,121(10):1211-1222.
  • 4Self M,Laqutin QV,Bowling B,et al.Six2 is required for suppression of nephrogenesis and progenitor renewal in the developing kidney[J].EMBO J,2006,25(21):5214-5228.
  • 5Liu TW,Ma ZG,Zhou Y,et al.Transplantation of mouse CGR8embryonic stem cells producing GDNF and TH protects against 6-hydroxydopamine neurotoxicity in the rat[J].Int J Biochem Cell Biol,2013,45(7):1265-1273.
  • 6Yue X,Hariri DJ,Cabollera B,and et al.Comparative study of the neurotrophic effects elicited by VEGF-B and GDNF in preclinical in vivo models of Parkinson's disease[J].Neuroscience,2014,258:385-400.
  • 7Redmond DE Jr,Mc Entire CR,Kingsbery JP,et al.Comparison of fetal mesencephalic grafts,AAV-delivered GDNF,and both combined in an MPTP-induced nonhuman primate Parkinson's model[J].Mol Ther,2013,21(12):2160-2168.
  • 8Cao JP,Li FZ,Zhu YY,and et al.Expressions and possible roles of GDNF receptors in the developing dopaminergic neurons[J].Brain Res Bull,2010,83(6):321-330.
  • 9Cao JP,Wang HJ,Yu JK,et al.The involvement of NF-kappa B p65/p52 in the effects of GDNF on DA neurons in early PD rats[J].Brain Res Bull,2008,76(5):505-511.
  • 10Cao JP,Wang HJ,Yu JK,and et al.Involvement of NCAM in the effects of GDNF on the neurite outgrowth in the dopamine neurons[J].Neuroscience Research,2008,61(4):390-397.

引证文献2

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部